Category: News & Events

First time a drug has decreased the rate of disease progression in addition to improving a significant proportion of patients with progressive MS Primary endpoint met (p=0.0051) Mean EDSS change…Continue readingMedDay reports positive pivotal Phase III study results with MD1003 in patients with Progressive Multiple Sclerosis

Edmond de Rothschild Investment Partners led the Series B financing alongside existing investors Sofinnova Partners and InnoBio. Large Venture also participated in the operation. Funds will drive a confirmatory phase…Continue readingMedDay Secures €34 Million ($38.5M) New Funding

Dr Frédéric Sedel prendra ses fonctions de Directeur scientifique à la fin du mois d’août Paris, France, 26 juillet 2018 – MedDay, société pharmaceutique pionnière dans le traitement des troubles…Continue readingMedDay nomme Christian Chavy, dirigeant reconnu de l’industrie pharmaceutique, au poste de Directeur Général

Paris, January 29 2015 – MedDay, an emerging biotechnology company focused on the treatment of nervous system disorders, today notes the acceptance of a manuscript relating to results from a…Continue readingMedDay Notes Acceptance of Manuscript into Journal of Multiple Sclerosis and Related Disorders

Edmond de Rothschild Investment Partners a mené le financement de série B aux côtés des investisseurs existants Sofinnova Partners et InnoBio. Large Venture a également participé à l’opération. Les fonds…Continue readingMedDay Pharmaceuticals réalise une nouvelle levée de fonds de 34 millions d’euros

– Second placebo controlled study with MD1003 in Multiple Sclerosis patients – Focus on patients with chronic visual loss following optic neuritis (ON) – Progressive ON sub-group analysis results consistent…Continue readingMedDay provides update on MS-ON study of MD-1003

~ Detailed Phase III data will be presented at AAN Annual Meeting in Clinical Trials Plenary Session on April 24th 2015 ~ Paris, France, April 17 2015 – MedDay, a…Continue readingMedDay announces its pivotal Phase III study of MD1003 in patients with Progressive Multiple Sclerosis meets primary endpoint

Paris, France, 2 September 2016 – MedDay, a biotechnology company focused on the treatment of nervous system disorders, announces the online publication of results from the previously reported Phase IIb/III,…Continue readingMedDay Announces Publication of MD1003 Phase IIb/III Study in the Multiple Sclerosis Journal

Paris, January 13th, 2015 – MedDay, a biotechnology company focused on the treatment of nervous system disorders, today announced the appointment of Philippe Goupit as an independent Non-Executive Director. Mr.…Continue readingMedDay appoints Philippe Goupit to its Board of Directors

Paris, France, 25 May 2016 – MedDay, a biotechnology company focused on the treatment of nervous system disorders, announces that an oral presentation entitled “High doses of biotin in progressive…Continue readingMedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial